Year: 2026
Type: article
Abstract: Mitochondrial DNA mutations can contribute to respiratory dysfunction and aging phenotypes, but they have not been established as the universal initiating cause of human aging.This Perspective compares mitochondrial transplantation with a proposed gene therapy strategy without presuming therapeutic superiority.Transplantation supplies functional organelles and has encouraging evidence in selected models and small clinical studies of acute injury.Gene transfer could support sustained endogenous mitochondrial maintenance, although that advantage remains untested for systemic aging.Four candidate mechanisms are considered: TERT associated mitochondrial protection, TFEB mediated lysosomal quality control, POLG and TFAM dependent genome maintenance with selective respiratory subunit supplementation, and FGF21 mediated metabolic signaling.Their evidence ranges from cellular mechanisms and animal studies to clinical experience in distinct disease indications.Important limitations include tumor promotion, inappropriate autophagy or genome packaging, endocrine adverse effects, vector toxicity, and uncertain coordination of multiple transgenes.A staged comparison should measure tissue specific target engagement, pathogenic heteroplasmy, respiratory function, organ performance, and long-term safety.Neither approach has demonstrated systemic human age reversal.The proposed framework is a falsifiable research agenda, with potential complementarity between organelle replacement and endogenous maintenance.
Source: Aging
Author: Patrick E. Sewell
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Keywords: mitochondrial dysfunction, mitochondrial transplantation, gene therapy, mitochondrial DNA mutations, respiratory dysfunction, telomerase reverse transcriptase, TFEB, DNA polymerase gamma, TFAM, FGF21, metabolic signaling, tumor promotion, autophagy, vector toxicity, heteroplasmy, aging reversal
Open Access status: hybrid
OpenAlex ID: W7226027193
